JP2021525266A5 - - Google Patents

Info

Publication number
JP2021525266A5
JP2021525266A5 JP2020565864A JP2020565864A JP2021525266A5 JP 2021525266 A5 JP2021525266 A5 JP 2021525266A5 JP 2020565864 A JP2020565864 A JP 2020565864A JP 2020565864 A JP2020565864 A JP 2020565864A JP 2021525266 A5 JP2021525266 A5 JP 2021525266A5
Authority
JP
Japan
Prior art keywords
composition according
composition
lopinavir
ritonavir
hpv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020565864A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021525266A (ja
JP7344911B2 (ja
Filing date
Publication date
Priority claimed from GBGB1808564.7A external-priority patent/GB201808564D0/en
Application filed filed Critical
Publication of JP2021525266A publication Critical patent/JP2021525266A/ja
Publication of JP2021525266A5 publication Critical patent/JP2021525266A5/ja
Application granted granted Critical
Publication of JP7344911B2 publication Critical patent/JP7344911B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020565864A 2018-05-24 2019-05-23 頸部障害の処置のためのロピナビルおよびリトナビル Active JP7344911B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1808564.7 2018-05-24
GBGB1808564.7A GB201808564D0 (en) 2018-05-24 2018-05-24 Treatments
PCT/IB2019/054292 WO2019224779A1 (en) 2018-05-24 2019-05-23 Lopinavir and ritonavir for the treatment of cervix disorders

Publications (3)

Publication Number Publication Date
JP2021525266A JP2021525266A (ja) 2021-09-24
JP2021525266A5 true JP2021525266A5 (https=) 2023-07-19
JP7344911B2 JP7344911B2 (ja) 2023-09-14

Family

ID=62812406

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020565864A Active JP7344911B2 (ja) 2018-05-24 2019-05-23 頸部障害の処置のためのロピナビルおよびリトナビル

Country Status (12)

Country Link
US (2) US11738024B2 (https=)
EP (1) EP3801509A1 (https=)
JP (1) JP7344911B2 (https=)
CN (1) CN112203656B (https=)
AU (1) AU2019274812B2 (https=)
BR (1) BR112020023964A2 (https=)
CA (1) CA3100425A1 (https=)
GB (1) GB201808564D0 (https=)
MX (1) MX2020012656A (https=)
SG (1) SG11202010138WA (https=)
WO (1) WO2019224779A1 (https=)
ZA (1) ZA202006324B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201808563D0 (en) 2018-05-24 2018-07-11 Univ Manchester Treatments
GB201808564D0 (en) 2018-05-24 2018-07-11 Douglas Pharmaceuticals Ltd Treatments
GB201907305D0 (en) 2019-05-23 2019-07-10 Douglas Pharmaceuticals Ltd Treatment of conditions
GB201917252D0 (en) * 2019-11-27 2020-01-08 Pharmaceutic compositions

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8822857D0 (en) 1988-09-29 1988-11-02 Patralan Ltd Pharmaceutical formulations
TR201809435T4 (tr) 2000-01-19 2018-07-23 Abbvie Inc Geliştirilmiş farmasötik formülasyonlar.
TWI231211B (en) 2001-05-01 2005-04-21 Abbott Lab Compositions and methods for enhancing the bioavailability of pharmaceutical agents
US20030129208A1 (en) 2002-01-07 2003-07-10 Alberts David S. Topical application of alpha-DFMO and anti-inflammatory drug for treatment of actinic keratoses
WO2004010937A2 (en) 2002-07-26 2004-02-05 Advanced Research & Technology Institute At Indiana University Method of treating cancer
BR0302523A (pt) 2003-07-23 2005-04-05 Cristalia Prod Quimicos Farm Composição farmacêutica estável para administração de inibidores da hiv protease e processo de obtenção de composição farmacêutica concentrada para a administração de inibidores da hiv protease
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
WO2005053694A1 (en) 2003-11-28 2005-06-16 The University Of Manchester Treatment of hpv infections and cancer
WO2008088806A1 (en) 2007-01-16 2008-07-24 Johns Hopkins University Combinational paradigm combating hiv, hiv/hsv, or hiv/hpv infections in humans using small molecular weight compounds from plants
WO2009129470A2 (en) 2008-04-18 2009-10-22 Nanobio Corporation Methods for treating herpes virus infections
GB201006038D0 (en) 2010-04-12 2010-05-26 Unilever Plc Improvements relating to antiviral compositions
US20140004186A1 (en) 2010-09-08 2014-01-02 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture comprising epa and dha in free acid form, a surfactant, and a statin
GB201115635D0 (en) * 2011-09-09 2011-10-26 Univ Liverpool Compositions of lopinavir and ritonavir
AU2014338707B2 (en) 2013-10-23 2020-06-04 The University Of Manchester Treatment of cancer and benign proliferative disorders
WO2016123541A2 (en) 2015-01-30 2016-08-04 Tobira Therapeutics, Inc. Cenicriviroc for the treatment of encephalitis infection
WO2019130341A1 (en) 2017-12-26 2019-07-04 Hetero Labs Limited Capsule compositions comprising lopinavir and ritonavir
GB201808564D0 (en) 2018-05-24 2018-07-11 Douglas Pharmaceuticals Ltd Treatments
GB201808571D0 (en) 2018-05-24 2018-07-11 Douglas Pharmaceuticals Ltd Pharmaceutical compositions
GB201808563D0 (en) 2018-05-24 2018-07-11 Univ Manchester Treatments
GB201808567D0 (en) 2018-05-24 2018-07-11 Douglas Pharmaceuticals Ltd Pharmaceutical compositions
GB201907305D0 (en) 2019-05-23 2019-07-10 Douglas Pharmaceuticals Ltd Treatment of conditions
GB201917252D0 (en) 2019-11-27 2020-01-08 Pharmaceutic compositions

Similar Documents

Publication Publication Date Title
JP2021525266A5 (https=)
US10543228B2 (en) Pharmaceutical preparation containing selenite or selenite-containing compounds for treating cervical dysplasia or carcinomas
US20240148729A1 (en) Lopinavir and ritonavir for the treatment of cervix disorders
CN101181636B (zh) 一种防治人乳头瘤病毒感染的复方疫苗组合物、复方疫苗阴道喷雾剂及其用途
Mudrikova et al. HPV-related anogenital disease and HIV infection: not always ‘ordinary’condylomata acuminata
CA2445506C (en) Use of sucralfate for the treatment of cervical erosion
Savoca et al. CO 2 laser vaporization as primary therapy for human papillomavirus lesions: A prospective observational study
CN114053475A (zh) 一种抗hpv医用妇科敷料
JP2021536454A5 (https=)
MA53482B1 (fr) Thérapie d'infections par le papillomavirus humain à haut risque
DeRossi et al. The management of oral human papillomavirus with topical cidofovir: a case report
Afshar et al. Clinical and Public Health Considerations for HPV Infection in Men: A Narrative Review
Mohseni Afshar et al. Clinical and public health considerations for hpv infection in men: A narrative review
CA2841851A1 (en) Composition and method for treating hpv
EP4046646A1 (en) Pharmaceutical composition for the treatment of hpv infections
RU2747987C1 (ru) Композиция для лечения латентной и субклинической папилломавирусной инфекции шейки матки и способ ее применения
Bannerjee Anogenital Warts
Pils et al. HPV-associated Dysplasia of Skin and Mucosa and Vaccination Options in Trans People
Condic et al. Severe Leukoplakia of the Vagina and Cervix Successfully Treated with Intravaginal Application of Topical Glucocorticoids
Conageski A 25-Year-Old Woman with LSIL Desiring HPV Vaccination
Qadri et al. Progress in the Treatment of Infantile Hemangioma
JP2023516153A5 (https=)
HK1243360B (zh) 用於治疗子宫颈非典型性增生或子宫颈癌的包含亚硒酸盐或含亚硒酸盐化合物的药物制剂
TRANSMITTED CONDYLOMATA ACUMINATA
CN101267812A (zh) 治疗皮肤病变的腙药剂